IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...
The U.S. Food and Drug Administration (FDA) approved Axonics (NASDAQ:AXNX) fourth-generation rechargeable sacral neuromodulation system (SNM). SNM is a therapy to treat urinary incontinence. The ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...
Axonics Inc. received FDA approval for its recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS) for bladder and bowel dysfunction. The F15’s primary cell requires no recharging ...
An Axonics sacral neuromodulation system sends electrical signals to nerves in the spinal cord to help regulate the bladder and bowels Device maker Axonics Inc. says its newest system designed to ...
NICE has said that the Axonics sacral neuromodulation (SNM) system can be used in the NHS to treat overactive bladder. The system works by using electrical impulses to stimulate the nerves in the ...
(RTTNews) - Shares of Axonics Inc. (AXNX) touched an all-time high of $72.03 in intraday trading Tuesday (Aug.17, 2021) as the company keeps exceeding its ambitious goals quarter over quarter, thanks ...
Medical technologies guidance 50 has been migrated to HealthTech guidance 554. The recommendations and accompanying content remain unchanged. This guidance replaces the NICE medtech innovation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback